Commercial funding received
Commercial funding received by the Nuffield Department of Population Health, University of Oxford
|
Project Name |
Sponsor |
From |
To |
Award |
Additional info |
|
3-C trial of transplant rejection |
Novartis Pharmaceuticals UK Ltd |
2009 |
2017 |
350 |
|
|
A multicenter international randomized double-blind placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in patients with chronic kidney disease treated with empagliflozin |
Boehringer Ingelheim International GmbH |
2023 |
2032 |
216,237 |
|
|
ACE trial of acarbose |
Bayer Plc |
2008 |
2022 |
135 |
* |
|
Africa Oxford (AfOx) Catalyst Grant |
Mastercard |
2022 |
1905 |
10 |
* |
|
An observational study of a multi-cancer early detection test (MCED) in individuals presenting with signs and symptoms of cancer in England |
GRAIL Bio UK Ltd |
2021 |
2026 |
70 |
* |
|
ASCEND PLUS |
Novo Nordisk A/S |
2021 |
2029 |
3,000 |
Plus drug supply |
|
ASCEND PLUS: A Study of Cardiovascular Events iN Diabetes |
Novo Nordisk A/S |
2021 |
2029 |
36,432 |
Plus drug supply |
|
ASCEND trial of aspirin and fish oils |
Bayer HealthCare LLC - USA |
2004 |
2013 |
53 |
Plus drug supply |
|
ASCEND trial of aspirin and fish oils |
Bayer AG |
2004 |
2017 |
1,826 |
|
|
ASCEND trial of aspirin and fish oils |
Solvay Pharmaceuticals GmbH |
2004 |
2013 |
584 |
|
|
ASCEND trial of aspirin and fish oils |
Abbott Product Operations AG |
2004 |
2017 |
1,532 |
|
|
Assessing the potential for SenseCam to fight the current global health crises of increasing obesity and physical inactivity |
Microsoft Research Ltd |
2010 |
2013 |
69 |
|
|
ATLAS trial of tamoxifen duration |
AstraZeneca UK Ltd |
2001 |
2018 |
508 |
|
|
BDI-Novartis Collaboration for AI in Medicine |
Novartis Pharma AG Switzerland |
2018 |
2027 |
404 |
* |
|
BEST-D pilot trial of vitamin D |
Tishcon |
2012 |
2014 |
0 |
Drug supply only |
|
BREXOME - rare variants in breast cancer |
Regeneron Pharmaceuticals Inc |
2020 |
2026 |
107 |
|
|
Burden of Antimicrobial Resistance and Antibiotic Treatment Failure in Low-, Middle- and High-Income Countries (BALANCE) & Burden of antibiotic resistance in neonates from developing societies (BARNARDS) II |
Ineos Group Limited |
2021 |
2031 |
144 |
* |
|
Can wearables improve the prediction of all-cause mortality, cardiovascular disease, and cancer in UK Biobank? |
Swiss Re Ltd |
2022 |
2026 |
645 |
|
|
Characterize the carriers of predicted loss-of –function variants in chymase |
Bayer AG |
2019 |
2021 |
297 |
|
|
Chinese case Control Study |
AstraZeneca AB |
2004 |
2015 |
154 |
Plus drug supply |
|
Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s Disease. |
Janssen Pharmaceutica NV |
2022 |
2023 |
85 |
|
|
Development of Digital Biomarkers for Dementia |
Roche Diagnostics International AG |
2016 |
2022 |
477 |
|
|
Development of Digital Biomarkers for Dementia. |
Eli Lilly and Company USA |
2016 |
2022 |
600 |
|
|
Device-measured physical activity in EMPA-ASi HFpEF trial |
Boehringer Ingelheim International GmbH |
2024 |
2028 |
378 |
|
|
Device-measured physical activity in EMPA-ASi HFrEF trial |
Boehringer Ingelheim International GmbH |
2025 |
2029 |
489 |
|
|
Diabetic Peripheral Neuropathy Treatment with Dorsal Root Ganglion Stimulation a Randomised Controlled Trial |
St Jude Medical Europe Inc |
2018 |
2020 |
52 |
* |
|
DNA EXTRACTION AND GENOTYPING IN CKB |
GSK Research & Development Ltd |
2011 |
2015 |
2,465 |
|
|
DOCTOR REFERRAL OF OVERWEIGHT PEOPLE TO LOW ENERGY TREATMENTS |
Cambridge World Heritage Centre Ltd |
2015 |
2020 |
35 |
* |
|
DYNAMIC CONSENT USCF |
Oxford University Innovation Ltd |
2015 |
2017 |
28 |
|
|
Economic Analysis ofExenatide Versus Placebo in Patients with Type 2 Diabetes and Inadequate Glycemic Control with Diet Alone, or Therapy with one, two or three Oral An tihyperglycemic Agents (EXSCEL) |
Amylin Pharmaceuticals Inc |
2009 |
2022 |
473 |
* |
|
Elinogrel feasibility trial |
Novartis |
2010 |
2011 |
500 |
|
|
Estimating acceptable non-inferiority margins for antibioti stewardship interventions using discrete choice experiments |
Mars Petcare UK |
2021 |
2024 |
25 |
|
|
FOXFIRE trial of chemotherapy with or without radioembolisation for bowel cancer that has spread to the liver |
Sirtex Technology Pty Ltd |
2009 |
2017 |
228 |
* |
|
FUWAI RESEARCH FACILITY |
Merck Sharp & Dohme LLC |
2010 |
2024 |
1,111 |
|
|
Heart Protection Study follow-up studies |
Merck: £1.2M; GlaxoSmithKline: $400K; Liposcience: £50K |
2003 |
2010 |
1,650 |
|
|
HPS 4/TIMI 65 - ORION-4. |
Novartis Pharmaceuticals Corporation |
2017 |
2030 |
85,399 |
|
|
HPS2 |
Merck & Co Inc |
2005 |
2015 |
52,196 |
|
|
Investigation of proteomics in the China Kadoorie Biobank |
Novo Nordisk Ltd |
2021 |
2022 |
341 |
|
|
IRIS Initiative Phase II - Genome sequencing |
Merck Sharp & Dohme (UK) Ltd |
2023 |
2027 |
856 |
|
|
Large-scale multi-omics assays in China Kadoorie Biobank |
Bayer AG |
2020 |
2025 |
1,577 |
|
|
LENS trial in Non-proliferative retinopathy in Scotland |
Mylan: free drug supply only |
2016 |
2022 |
0 |
Drug supply only |
|
Leveraging Large Scale Biobanks to Investigate Digital Biomarkers for the Early Identification of Chronic Obstructive Pulmonary Disease |
GSK Research & Development Ltd |
2025 |
2028 |
681 |
|
|
MaatHRI Project (Ultromics) |
Ultromics Limited |
2018 |
2022 |
79 |
|
|
Measuring sleep characteristics using machine learning in wearable datasets. |
Novo Nordisk A/S |
2020 |
(blank) |
135 |
|
|
Mexico City Prospective Study - Amended and Restated Research Collaboration Agreement (Regeneron) |
Regeneron Pharmaceuticals Inc |
2021 |
2029 |
1,780 |
|
|
Mexico City Prospective Study - Amended and Restated Research Collaboration Agreement (Astrazeneca) |
AstraZeneca UK Ltd |
2021 |
2029 |
1,809 |
|
|
NAVIGATOR - HEALTH ECONOMICS PAPER |
Novartis Pharmaceuticals Corporation |
2013 |
2014 |
15 |
* |
|
Next generation sequencing analysis - a clinical study |
Life Technologies Corporation |
2011 |
2014 |
125 |
* |
|
NN-BDI Partnership: Integration of medical imaging and genetic data using machine learning for identification of micro and macro vascular disease targets |
Novo Nordisk A/S |
2021 |
2026 |
1,154 |
* |
|
NN-Big Data Partnership: Using data from wearable devices to identify novel targets for cardiometabolic disease (obesity, T2DM, NAFLD, & heart failure) |
Novo Nordisk A/S |
2021 |
2025 |
1,052 |
* |
|
Non invasive rapid assessment of liver disease using magnetic resonance |
Perspectum Ltd |
2016 |
2019 |
273 |
* |
|
Novartis EPSRC Centre for Doctoral Training in Healthcare Data Science DPhil Studentship |
Novartis Pharma AG Switzerland |
2024 |
2028 |
160 |
|
|
Novo Nordisk Fellowship Programme Renewal |
Novo Nordisk A/S |
2021 |
2034 |
460 |
* |
|
Novo-Nordisk Postdoctoral Fellowship Programme |
Novo Nordisk A/S |
2013 |
2025 |
217 |
* |
|
ORION-17 |
Novartis Pharma AG Switzerland |
2020 |
2023 |
1,059 |
|
|
Oxford-GSK Institute of Molecular & Computational Medicine |
GSK Research & Development Ltd |
2021 |
2028 |
263 |
* |
|
Oxford-GSK Study of COPD Using CKB Data |
GSK Research & Development Ltd |
2012 |
2015 |
1,110 |
|
|
Oxford-Janssen Human Genomics Fellowship Programme |
Janssen Biotech |
2020 |
2025 |
30 |
|
|
OxPod - Podium Institute |
Podium Analytics |
2021 |
2027 |
31 |
* |
|
Pharmacogenomic analysis of the Heart Protection Study using a CAD polygenic risk score |
Regeneron Pharmaceuticals Inc |
2020 |
2026 |
143 |
|
|
PROCARDIS genetic study |
AstraZeneca: £1.7M |
1998 |
2011 |
1,700 |
|
|
Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (REVEAL) |
Merck Sharp & Dohme LLC |
2010 |
2022 |
108,110 |
|
|
Second Heart Protection Study (SEARCH) |
Merck & Co Inc |
1997 |
2009 |
22,727 |
Plus drug supply |
|
SHARP |
Merck & Co Inc |
2001 |
2017 |
39,617 |
Plus drug supply |
|
SHARP 3 |
Boehringer Ingelheim International GmbH |
2022 |
2023 |
1,809 |
|
|
SHARP-2 EMPRESS. |
Boehringer Ingelheim International GmbH |
2017 |
2029 |
106,252 |
|
|
Small open reading frames in drug discovery: from genetics to mechanisms to new therapies |
Novo Nordisk A/S |
2022 |
2026 |
48 |
* |
|
STICS (STATIN THERAPY IN CARDIAC SURGERY) ASTRAZENECA GRANT |
AstraZeneca UK Ltd |
2011 |
2016 |
61 |
|
|
TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin |
Merck & Co Inc |
2008 |
2023 |
140 |
* |
|
The 3C Study - CAMPATH |
John Wyeth & Brother Limited |
2009 |
2017 |
530 |
|
|
THE ECONOMIC BURDEN OF MALIGNANT NEOPLASMS IN THE EU |
Pfizer Ltd |
2011 |
2012 |
37 |
|
|
The Oxford Participation & Activities Questionnaire (Ox-PAQ): Phase 2 Study Protocol - Actelion unrestricted grant |
Actelion Pharmaceuticals Ltd |
2015 |
2016 |
58 |
|
|
The Oxford-Novartis Collaboration for AI in Medicine |
Novartis Pharma AG Switzerland |
2024 |
2027 |
322 |
* |
|
Therapies for Influenza |
Oxon Epidemiology Limited |
2019 |
2023 |
77 |
|
|
Thrombotic Microangiopathy associated Pregnancy Acute Kidney Injury in the United Kingdom: Incidence, Outcomes and Risk Factors |
Alexion Pharmaceuticals Inc. |
2021 |
2022 |
32 |
|
|
UK HEART AND RENAL PROTECTION (UK-HARP)-III: LCZ696 IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PILOT STUDY |
Novartis Pharma AG Switzerland |
2013 |
2018 |
2,574 |
|
|
USING HUMAN GENETICS TO VALIDATE THERAPEUTIC TARGETS RELATED TO CLINICAL MEASURES AND RISK FOR CARDIOVASCULAR EVENTS |
Merck Sharp & Dohme LLC |
2012 |
2014 |
214 |
|
|
Using Whole Genome Sequencing Datasets to Identify Novel Disease Genes and Mechanisms. |
GSK Research & Development Ltd |
2020 |
2024 |
317 |
* |
Updated on 19-May-26
* Funds received by Nuffield Department of Population Health for collaborative research projects led by other Institutions or Oxford University departments